Clinical Trials List
Protocol NumberGCT1184-09
NCT Number(ClinicalTrials.gov Identfier)NCT07539311
Not yet recruiting
2026-07-01 - 2028-11-30
Phase II
Not yet recruiting1
A Phase 2, Open-label, Multicohort, Study of Rinatabart Sesutecan (Rina-S) in Participants with Advanced Gastrointestinal (GI) Cancers
-
Trial Applicant
IQVIA RDS Taiwan Ltd.
-
Sponsor
IQVIA Solutions Taiwan Ltd.
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/09/21
Investigators and Locations
Co-Principal Investigator
- Yi-Ping Hung 無
- 姜乃榕 無
- 唐振育 無
- San-Chi Chen 無
- Tien-Hua Chen 無
- Chien-An Liu 無
- 邱乃祈 無
Co-Principal Investigator
- 郭弘揚 無
- 梁逸歆 無
- 吳宗哲 無
- Chih-Hung Hsu 無
- Jih-Hsiang Lee 無
- Kun-Huei Yeh 無
- 莊建淮 無
- 徐偉勛 無
- 陳國興 無
Co-Principal Investigator
- Chang-Fang Chiu 無
- Chi-Ching Chen 無
- 王秀慈 無
- 陳珈妤 無
Co-Principal Investigator
- Wei-Chih Su 無
- Yen-Cheng Chen 無
- 張琮琨 無
- 黃敬文 無
- 陳伯榕 無
- 蔡祥麟 無
Principal Investigator
Jen-Shi Chen
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Condition/Disease
Gastrointestinal Cancers
Objectives
This Phase 2 study will be conducted in different countries around the world with up to about 160 participants.
The purpose of this study is to evaluate how well Rina-S works against GI cancers.
The medication in this study is Rina-S monotherapy (by itself; no other cancer treatments). All participants will receive active drug; no one will be given placebo.
Participation in the study will require visits to the study site(s). During site visits, there will be various tests (such as blood draws) and procedures (such as recording of heart activity, imaging/X-rays) to monitor whether the study treatment is safe and effective.
The duration of the study will be different for every participant, but an average study duration of 22 months is expected for participants. This will include a treatment period (expected to last an average of 12 months), plus data collection periods before and after treatment. Participants will be asked to attend 1 to 5 visits at the study clinic for each cycle (duration of an individual cycle is 21 days). If a participant's cancer stays the same or gets better, and there are not any serious problems, participants can keep getting study treatment for as long as the study is open.
Test Drug
Rina‑S
Active Ingredient
Rinatabart sesutecan
Dosage Form
Lyophilized powder for injection
Dosage
amount 1
Endpoints
Confirmed Objective Response Rate (ORR) Up to approximately 22 months
Inclution Criteria
Participant has histologically or cytologically confirmed GI cancer.
Participant has documented metastatic or unresectable disease, not amenable to treatment with curative intent.
Participant has measurable disease per the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 at baseline.
Participant must have radiological disease progression while on or after receiving the most recent regimen.
Participant has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Participant has life expectancy ≥3 months.
Participant must be able to provide a newly obtained or archival tissue sample.
Participant must have adequate organ and bone marrow function, per laboratory test results prior to Rina-S administration.
Participant has documented metastatic or unresectable disease, not amenable to treatment with curative intent.
Participant has measurable disease per the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 at baseline.
Participant must have radiological disease progression while on or after receiving the most recent regimen.
Participant has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Participant has life expectancy ≥3 months.
Participant must be able to provide a newly obtained or archival tissue sample.
Participant must have adequate organ and bone marrow function, per laboratory test results prior to Rina-S administration.
Exclusion Criteria
Participant has clinically significant non-malignant gastrointestinal disorders, including but not limited to, diarrhea > grade 1, ulcerative colitis, inflammatory bowel disease.
Participants with recent (up to 4 weeks) history of significant gastrointestinal bleeding, current cancer related ulcerations, fistula, abscess or recent perforation (within 4 to 6 weeks).
Participant has a past or current malignancy other than the inclusion diagnosis before the planned first dose of trial treatment, or any evidence of residual disease from a previously diagnosed malignancy.
Participants with newly identified or known unstable (eg, progressing brain metastases) or symptomatic central nervous system (CNS) metastases or history of carcinomatous meningitis (also known as leptomeningeal disease).
Prior treatment with topoisomerase-1 inhibitor containing antibody-drug conjugate (ADC).
Treatment with an anticancer agent within 28 days prior to the first dose of trial treatment.
Participants with recent (up to 4 weeks) history of significant gastrointestinal bleeding, current cancer related ulcerations, fistula, abscess or recent perforation (within 4 to 6 weeks).
Participant has a past or current malignancy other than the inclusion diagnosis before the planned first dose of trial treatment, or any evidence of residual disease from a previously diagnosed malignancy.
Participants with newly identified or known unstable (eg, progressing brain metastases) or symptomatic central nervous system (CNS) metastases or history of carcinomatous meningitis (also known as leptomeningeal disease).
Prior treatment with topoisomerase-1 inhibitor containing antibody-drug conjugate (ADC).
Treatment with an anticancer agent within 28 days prior to the first dose of trial treatment.
The Estimated Number of Participants
-
Taiwan
10 participants
-
Global
160 participants
